Gene therapy for relapsed breast cancer

Shunji Takahashi, Yoshikazu Sugimoto

Research output: Contribution to journalArticle

Abstract

Gene therapy for advanced breast cancer is anticipated to be a useful therapeutic approach. Strategies in ongoing clinical protocols can be divided into four groups: (1) suppression of oncogenes or transfer of tumor-suppressor genes: (2) enhancement of immunological response: (3) transfer of suicide genes: (4) protection of bone marrow using drug resistance genes. We have started a clinical study of multidrug resistance (MDR1) gene therapy. Patients received high dose chemotherapy and autologous peripheral blood stem cell transplantation (PBSCT) with MDR1-transduced hematopoietic cells, and then were treated with docetaxel. Three patients have been treated so far, and in vivo enrichment of MDR1-transduced cells with docetaxel treatment has been seen. There has been no apparent adverse effect from the MDR1 gene transfer.

Original languageEnglish
Pages (from-to)563-569
Number of pages7
JournalNippon rinsho. Japanese journal of clinical medicine
Volume64
Issue number3
Publication statusPublished - 2006
Externally publishedYes

Fingerprint

docetaxel
Genetic Therapy
Breast Neoplasms
Genes
MDR Genes
Peripheral Blood Stem Cell Transplantation
Clinical Protocols
Tumor Suppressor Genes
Oncogenes
Drug Resistance
Suicide
Bone Marrow
Drug Therapy
Therapeutics

Cite this

Gene therapy for relapsed breast cancer. / Takahashi, Shunji; Sugimoto, Yoshikazu.

In: Nippon rinsho. Japanese journal of clinical medicine, Vol. 64, No. 3, 2006, p. 563-569.

Research output: Contribution to journalArticle

@article{256f66188e464284891031c145167a23,
title = "Gene therapy for relapsed breast cancer",
abstract = "Gene therapy for advanced breast cancer is anticipated to be a useful therapeutic approach. Strategies in ongoing clinical protocols can be divided into four groups: (1) suppression of oncogenes or transfer of tumor-suppressor genes: (2) enhancement of immunological response: (3) transfer of suicide genes: (4) protection of bone marrow using drug resistance genes. We have started a clinical study of multidrug resistance (MDR1) gene therapy. Patients received high dose chemotherapy and autologous peripheral blood stem cell transplantation (PBSCT) with MDR1-transduced hematopoietic cells, and then were treated with docetaxel. Three patients have been treated so far, and in vivo enrichment of MDR1-transduced cells with docetaxel treatment has been seen. There has been no apparent adverse effect from the MDR1 gene transfer.",
author = "Shunji Takahashi and Yoshikazu Sugimoto",
year = "2006",
language = "English",
volume = "64",
pages = "563--569",
journal = "Nihon rinsho. Japanese journal of clinical medicine",
issn = "0047-1852",
publisher = "Nipponrinsho Co., Inc.",
number = "3",

}

TY - JOUR

T1 - Gene therapy for relapsed breast cancer

AU - Takahashi, Shunji

AU - Sugimoto, Yoshikazu

PY - 2006

Y1 - 2006

N2 - Gene therapy for advanced breast cancer is anticipated to be a useful therapeutic approach. Strategies in ongoing clinical protocols can be divided into four groups: (1) suppression of oncogenes or transfer of tumor-suppressor genes: (2) enhancement of immunological response: (3) transfer of suicide genes: (4) protection of bone marrow using drug resistance genes. We have started a clinical study of multidrug resistance (MDR1) gene therapy. Patients received high dose chemotherapy and autologous peripheral blood stem cell transplantation (PBSCT) with MDR1-transduced hematopoietic cells, and then were treated with docetaxel. Three patients have been treated so far, and in vivo enrichment of MDR1-transduced cells with docetaxel treatment has been seen. There has been no apparent adverse effect from the MDR1 gene transfer.

AB - Gene therapy for advanced breast cancer is anticipated to be a useful therapeutic approach. Strategies in ongoing clinical protocols can be divided into four groups: (1) suppression of oncogenes or transfer of tumor-suppressor genes: (2) enhancement of immunological response: (3) transfer of suicide genes: (4) protection of bone marrow using drug resistance genes. We have started a clinical study of multidrug resistance (MDR1) gene therapy. Patients received high dose chemotherapy and autologous peripheral blood stem cell transplantation (PBSCT) with MDR1-transduced hematopoietic cells, and then were treated with docetaxel. Three patients have been treated so far, and in vivo enrichment of MDR1-transduced cells with docetaxel treatment has been seen. There has been no apparent adverse effect from the MDR1 gene transfer.

UR - http://www.scopus.com/inward/record.url?scp=33744759588&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33744759588&partnerID=8YFLogxK

M3 - Article

VL - 64

SP - 563

EP - 569

JO - Nihon rinsho. Japanese journal of clinical medicine

JF - Nihon rinsho. Japanese journal of clinical medicine

SN - 0047-1852

IS - 3

ER -